Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.
about
A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzymeBioactive peptides from muscle sources: meat and fishDesign of potent and selective human cathepsin K inhibitors that span the active siteNatural Inhibitors of Snake Venom Metalloendopeptidases: History and Current ChallengesColubrid Venom Composition: An -Omics PerspectiveA brief history of macromolecular crystallography, illustrated by a family tree and its Nobel fruitsAngiotensin Converting Enzyme (ACE) Inhibitor Extends Caenorhabditis elegans Life SpanStructural characterization of angiotensin I-converting enzyme in complex with a selenium analogue of captoprilCrystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzymeStructural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d)Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular DiseaseA simple radioassay for angiotensin-converting enzymeEffect of angiotensin-converting enzyme inhibitor YS980 on prostaglandin synthesis in rabbit kidney medulla slicesCaptopril and atenolol combined with hydrochlorothiazide in essential hypertension.Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtypeMolecular cloning and expression of rat brain endopeptidase 3.4.24.16Argininosuccinate synthetase is a functional target for a snake venom anti-hypertensive peptide: role in arginine and nitric oxide production.Chemical ecology: a view from the pharmaceutical industryRXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.Locally administrated perindopril improves healing in an ovariectomized rat tibial osteotomy modelA method for screening enzyme inhibitors using size exclusion chromatography and ESI-LC-MS/MS.Screening of small molecule interactor library by using in-cell NMR spectroscopy (SMILI-NMR).Oral converting enzyme inhibitor in malignant hypertension.Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets.Hypertension symposium: newer topics on normal and abnormal blood pressure regulatory mechanisms.ACE and platelet aggregation inhibitors from Tamarix hohenackeri Bunge (host plant of Herba Cistanches) growing in Xinjiang.N- versus C-domain selectivity of catalytic inactivation of human angiotensin converting enzyme by lisinopril-coupled transition metal chelatesAngiotensin-I-converting enzyme (ACE) inhibitors from marine resources: prospects in the pharmaceutical industry.Adverse drug reaction monitoring with angiotensin converting enzyme inhibitors: A prospective, randomized, open-label, comparative studyEvolution of drugs that preserve renal function.Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study.Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase.Neutral endopeptidase and kininase II mediate glucocorticoid inhibition of neurogenic inflammation in the rat trachea.Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertensionDegradation of neurotensin by rat brain synaptic membranes: involvement of a thermolysin-like metalloendopeptidase (enkephalinase), angiotensin-converting enzyme, and other unidentified peptidases.The catalytic mechanism of angiotensin converting enzyme.Renin-angiotensin system in the kidney: What is new?Unexpected binding of an octapeptide to the angiotensin II receptor.Characterization and localization of mitochondrial oligopeptidase (MOP) (EC 3.4.24.16) activity in the human cervical adenocarcinoma cell line HeLa.The renin/angiotensin system.
P2860
Q24306614-B72830D1-19C6-4B9C-9A94-7EB6E1565EC5Q24610066-C057935D-8C25-454C-B9BF-CB88D10753E5Q24651743-AC928148-2C48-4105-AA9A-A0ED31E0B463Q26738414-C00E4D2E-80BA-4D58-A4A8-E737B19BDFA5Q26741753-E18BC882-53B4-40FE-AD61-45C86248E1ABQ26823889-078F4FC3-CC9E-44C5-BF4F-E7C797BF4B37Q27309126-B00257BE-6D4E-49D5-9ABA-22D1B6B31A79Q27671388-63345624-09CE-44B3-B0A3-C564EBBE3C4AQ27680712-BAE7CAC5-01DC-4425-A616-32E40AB36CA2Q27730901-46223B3D-1321-47AC-A9EF-B304A8C58BD9Q28077454-1441F02F-E94E-49DF-B3B1-20807369C11DQ28321561-338A8EC8-36B7-4E43-B8D1-7D6BB9A368B7Q28361641-95660A0A-0E26-4418-B8E6-8A954B4D227BQ28367116-36B84480-B049-4DAD-A0C6-D1E3CEB5850EQ28378367-9C47B570-ECCC-4271-8F36-19070B1D1D21Q28646024-B6AF8A0D-F1D1-4F38-86EC-648E49B2D6F0Q29144136-111D9A3C-3651-4123-A700-B6B863869441Q30418854-EDD08BE6-946F-4A95-91FE-B4067D8CB439Q30670251-03B4917D-F313-48F6-850E-2A9A0E220DA8Q31051550-FFFBA8AC-6EEC-4CE8-8E84-455639299383Q31146595-0E3A3E92-73F7-4A1B-B942-9384796584B5Q33440793-B79C59CE-A885-4A98-9A74-1C39225B51DDQ33476828-25038D01-B09C-4388-A202-A71690248C90Q33556394-C1EC9F07-3FE5-47E7-A689-91451C9F23F7Q33580769-B067734B-B5A9-491E-9A12-E949E778A582Q33722830-0510D061-9FDA-4514-9966-66761AE6646EQ33737152-E03BDC11-A7F6-4793-8542-0A30C385DFBBQ33837007-4D271B39-C7E3-4B02-AB6A-92335B13324BQ33913089-FACA13E1-84E1-48D6-954C-24AC81C8CEAEQ34024129-28384725-23EC-4BDC-961A-101197BD220AQ34068900-00037462-3C4C-432B-BF14-C578DB0CB279Q34207289-F2A363FC-92B6-4247-9D9F-A2970CDE6C5FQ34225017-D6CC0F09-2D1D-4EE5-A11B-BCF0590D128EQ34247173-D16F95BC-371D-4BE2-90BE-EB15F3097DAAQ34254747-96CC7172-1915-4C54-9D3B-90B19BEF5C4AQ34255117-A18F6CA1-3F36-47D3-85CE-E656FD9ECCCDQ34367671-9476D791-E163-4EE8-AFD2-1541A748FAFAQ34380975-6EDB07E1-2B74-46BB-A7E5-68A251802F9EQ34435409-3D8E0573-59E0-45BC-B2A5-EE7222785844Q34449718-92F8AB81-EFB0-4891-8A24-80EB8F91FE41
P2860
Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.
description
1977 nî lūn-bûn
@nan
1977 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1977 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
name
Design of specific inhibitors ...... ctive antihypertensive agents.
@ast
Design of specific inhibitors ...... ctive antihypertensive agents.
@en
Design of specific inhibitors ...... ctive antihypertensive agents.
@nl
type
label
Design of specific inhibitors ...... ctive antihypertensive agents.
@ast
Design of specific inhibitors ...... ctive antihypertensive agents.
@en
Design of specific inhibitors ...... ctive antihypertensive agents.
@nl
prefLabel
Design of specific inhibitors ...... ctive antihypertensive agents.
@ast
Design of specific inhibitors ...... ctive antihypertensive agents.
@en
Design of specific inhibitors ...... ctive antihypertensive agents.
@nl
P2093
P356
P1433
P1476
Design of specific inhibitors ...... ctive antihypertensive agents.
@en
P2093
P304
P356
10.1126/SCIENCE.191908
P407
P577
1977-04-01T00:00:00Z